104 related articles for article (PubMed ID: 23397985)
1. YKL-40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis.
Imai Y; Aochi S; Iwatsuki K; Sano H; Yamanishi K
J Dermatol; 2013 Apr; 40(4):294-6. PubMed ID: 23397985
[No Abstract] [Full Text] [Related]
2. Plasma YKL-40: a potential biomarker for psoriatic arthritis?
Jensen P; Wiell C; Milting K; Poggenborg RP; Østergaard M; Johansen JS; Skov L
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):815-9. PubMed ID: 22621388
[TBL] [Abstract][Full Text] [Related]
3. Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings.
Ahmed SF; Attia EA; Saad AA; Sharara M; Fawzy H; El Nahrery EM
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):682-8. PubMed ID: 25087779
[TBL] [Abstract][Full Text] [Related]
4. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
[TBL] [Abstract][Full Text] [Related]
5. Chitinase-3-like Protein 1 (YKL-40): Novel Biomarker of Hidradenitis Suppurativa Disease Activity?
Matusiak Ł; Salomon J; Nowicka-Suszko D; Bieniek A; Szepietowski JC
Acta Derm Venereol; 2015 Jul; 95(6):736-7. PubMed ID: 25655759
[No Abstract] [Full Text] [Related]
6. Serum YKL-40 concentrations are elevated and correlated with disease severity in patients with obstructive sleep apnea syndrome.
Wang X; Xing GH
Scand J Clin Lab Invest; 2014 Jan; 74(1):74-8. PubMed ID: 24405178
[TBL] [Abstract][Full Text] [Related]
7. YKL-40 (chitinase 3-like-1) as a biomarker for psoriasis vulgaris and pustular psoriasis.
Imai Y; Tsuda T; Aochi S; Futatsugi-Yumikura S; Sakaguchi Y; Nakagawa N; Iwatsuki K; Yamanishi K
J Dermatol Sci; 2011 Oct; 64(1):75-7. PubMed ID: 21782391
[No Abstract] [Full Text] [Related]
8. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters.
Matsumoto T; Tsurumoto T
Clin Exp Rheumatol; 2001; 19(6):655-60. PubMed ID: 11791636
[TBL] [Abstract][Full Text] [Related]
9. Analysis of YKL-40 acute-phase protein and interleukin-6 levels in periodontal disease.
Keles ZP; Keles GC; Avci B; Cetinkaya BO; Emingil G
J Periodontol; 2014 Sep; 85(9):1240-6. PubMed ID: 24635545
[TBL] [Abstract][Full Text] [Related]
10. Pretransplant serum human chitinase-like glycoprotein YKL-40 concentrations independently predict bronchiolitis obliterans development in lung transplant recipients.
Jaksch P; Taghavi S; Klepetko W; Salama M
J Thorac Cardiovasc Surg; 2014 Jul; 148(1):273-81. PubMed ID: 24685381
[TBL] [Abstract][Full Text] [Related]
11. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma.
Konradsen JR; James A; Nordlund B; Reinius LE; Söderhäll C; Melén E; Wheelock AM; Lödrup Carlsen KC; Lidegran M; Verhoek M; Boot RG; Dahlén B; Dahlén SE; Hedlin G
J Allergy Clin Immunol; 2013 Aug; 132(2):328-35.e5. PubMed ID: 23628340
[TBL] [Abstract][Full Text] [Related]
12. Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis.
Salomon J; Matusiak Ł; Nowicka-Suszko D; Szepietowski JC
Mediators Inflamm; 2017; 2017():9538451. PubMed ID: 28932021
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of YKL-40 concentrations in nonmyeloablative conditioning allogeneic hematopoietic cell transplantation.
Mørup AM; Kornblit B; Johansen JS; Masmas TN; Madsen HO; Vindeløv L; Garred P
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1299-307. PubMed ID: 21232622
[TBL] [Abstract][Full Text] [Related]
14. Serum YKL-40 levels are altered in endometriosis.
Tuten A; Kucur M; Imamoglu M; Oncul M; Acikgoz AS; Sofiyeva N; Ozturk Z; Kaya B; Oral E
Gynecol Endocrinol; 2014 May; 30(5):381-4. PubMed ID: 24533749
[TBL] [Abstract][Full Text] [Related]
15. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
16. YKL-40 as a marker of joint involvement in inflammatory bowel disease.
Bernardi D; Podswiadek M; Zaninotto M; Punzi L; Plebani M
Clin Chem; 2003 Oct; 49(10):1685-8. PubMed ID: 14500601
[No Abstract] [Full Text] [Related]
17. YKL-40 protein is a marker of asthma.
Specjalski K; Jassem E
J Asthma; 2011 Oct; 48(8):767-72. PubMed ID: 21899483
[TBL] [Abstract][Full Text] [Related]
18. Serum YKL-40 levels as a prognostic factor in patients with intracerebral hemorrhage.
Jiang YX; Zhang GH; Wang ZM; Yang H
Clin Biochem; 2014 Dec; 47(18):302-6. PubMed ID: 25262987
[TBL] [Abstract][Full Text] [Related]
19. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
[No Abstract] [Full Text] [Related]
20. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?
Erfan G; Guzel S; Alpsoy S; Rifaioglu EN; Kaya S; Kucukyalcın V; Topcu B; Kulac M
Mol Cell Biochem; 2015 Feb; 400(1-2):207-12. PubMed ID: 25421412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
